More recently, the SU R21-MatrixM vaccine, also approved for use in Ghana and using the same CS protein as RTS,S but with an increased ratio of CS to HBsAg, has also exhibited significant efficacy in a seasonal malaria setting. This evidence concerns the gene CS and malaria.